ArticleBlood2012
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia.Haematologica · 2026Article
- The LIM-domain-only protein LMO2 and its binding partner LDB1 are differentially required for class switch recombination.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- GPRASP protein deficiency triggers lymphoproliferative disease by affecting B-cell differentiation.HemaSphere · 2024Article
- Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma.Virchows Archiv : an international journal of pathology · 2024Article
- Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer.Journal of translational medicine · 2024Article
- Lung Cancer Gene Regulatory Network of Transcription Factors Related to the Hallmarks of Cancer.Current issues in molecular biology · 2023Article
- Article
- Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis.Nature communications · 2022Article
- Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates withLeukemia & lymphoma · 2021Article
- New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).Brain and behavior · 2021Article
- Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.Journal of hematology & oncology · 2021Article
- Biochemical Feature of LMO2 Interactome and LMO2 Function Prospect.Medical science monitor basic research · 2020Article
- Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.Cancers · 2020Article
- LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.Cancer cell · 2019Article
- The LL-100 panel: 100 cell lines for blood cancer studies.Scientific reports · 2019Article
- Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.The EMBO journal · 2018Article
- Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.British journal of pharmacology · 2017Review
- Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.Molecular immunology · 2017Article
- LMO2 is required for TAL1 DNA binding activity and initiation of definitive haematopoiesis at the haemangioblast stage.Nucleic acids research · 2017Article
- LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 3 countries.
Funding
Abstract
LMO2 regulates gene expression by facilitating the formation of multipartite DNA-binding complexes. In B cells, LMO2 is specifically up-regulated in the germinal center (GC) and is expressed in GC-derived non-Hodgkin lymphomas. LMO2 is one of the most powerful prognostic indicators in diffuse large B-cell (DLBCL) patients. However, its function in GC B cells and DLBCL is currently unknown. In this study, we characterized the LMO2 transcriptome and transcriptional complex in DLBCL cells. LMO2 regulates genes implicated in kinetochore function, chromosome assembly, and mitosis. Overexpression of LMO2 in DLBCL cell lines results in centrosome amplification. In DLBCL, the LMO2 complex contains some of the traditional partners, such as LDB1, E2A, HEB, Lyl1, ETO2, and SP1, but not TAL1 or GATA proteins. Furthermore, we identified novel LMO2 interacting partners: ELK1, nuclear factor of activated T-cells (NFATc1), and lymphoid enhancer-binding factor1 (LEF1) proteins. Reporter assays revealed that LMO2 increases transcriptional activity of NFATc1 and decreases transcriptional activity of LEF1 proteins. Overall, our studies identified a novel LMO2 transcriptome and interactome in DLBCL and provides a platform for future elucidation of LMO2 function in GC B cells and DLBCL pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.